US FDA approves Sanofi's wearable injector form of blood cancer drug

FDA approved Sanofi’s blood cancer drug Sarclisa for multiple myeloma with an on-body wearable injector that allows subcutaneous dosing. The new administration route is positioned as a less burdensome alternative to intravenous infusions, potentially supporting broader adoption among patients.

Analysis

FDA approved Sanofi’s blood cancer drug Sarclisa for multiple myeloma with an on-body wearable injector that allows subcutaneous dosing. The new administration route is positioned as a less burdensome alternative to intravenous infusions, potentially supporting broader adoption among patients.